Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CODY
NCT04893486Phase 2Completed
- Sponsor
- Palvella Therapeutics
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sirolimus in nevoid basal cell carcinoma syndrome (NBCCS), sponsored by Palvella Therapeutics. Started May 2021; status: completed.
02
Drugs
sirolimus
03
Conditions
nevoid basal cell carcinoma syndrome (NBCCS)
Beyond the preview
Go deeper on NCT04893486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893486.